Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Reduced by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. cut its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 21.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 615,131 shares of the company's stock after selling 172,405 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.37% of Y-mAbs Therapeutics worth $4,816,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Y-mAbs Therapeutics during the 4th quarter worth about $46,000. Wells Fargo & Company MN lifted its position in Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after buying an additional 6,131 shares in the last quarter. SG Americas Securities LLC grew its stake in Y-mAbs Therapeutics by 30.7% during the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after buying an additional 4,163 shares during the period. XTX Topco Ltd increased its position in shares of Y-mAbs Therapeutics by 83.8% in the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock worth $163,000 after acquiring an additional 9,468 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Y-mAbs Therapeutics by 9.4% in the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after acquiring an additional 1,903 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Trading Down 3.1%

YMAB stock traded down $0.13 during midday trading on Wednesday, hitting $4.10. 191,700 shares of the company's stock were exchanged, compared to its average volume of 313,339. The firm has a 50 day moving average price of $4.44 and a 200-day moving average price of $6.91. The stock has a market capitalization of $185.66 million, a price-to-earnings ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics, Inc. has a 12-month low of $3.55 and a 12-month high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. On average, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 10,810 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 22.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Truist Financial decreased their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. HC Wainwright decreased their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Monday. Oppenheimer lowered their target price on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research note on Wednesday, May 14th. Morgan Stanley dropped their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. Finally, Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Y-mAbs Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $16.60.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.